The OptimPacing trial randomized patients across 17 centers in mainland China, Hong Kong, the United Kingdom, Poland and the United States. Investigators enrolled 685 adults with second‑degree or complete atrioventricular block, or with atrial fibrillation and symptomatic bradycardia. The cohort’s mean age was 68.4 years and 57.5% were men. Most participants began the study with a normal left ventricular ejection fraction. Randomization allocated roughly half the participants to left bundle branch pacing and half to right ventricular pacing.
Study teams collected baseline data before implantation, obtained immediate post‑implant assessments, reassessed at 6 and 12 months, and then performed annual follow‑up. The protocol included clinical-event capture, echocardiographic surveillance and device interrogation. All major health events were independently adjudicated by a committee blinded to treatment allocation.
Investigators defined the primary composite outcome as death, hospitalization for heart failure and pacing‑induced cardiomyopathy. Data reported from a planned interim analysis showed the composite occurred in 8.5% of patients assigned to left bundle branch pacing versus 19.2% assigned to right ventricular pacing. The authors reported a 59% lower risk for the composite outcome in the left bundle branch pacing arm compared with the standard right ventricular approach.
At four years the cumulative estimates mirrored the interim numbers: 8.5% in the left bundle group and 19.2% in the right ventricular group had experienced the composite outcome. No participants in the left bundle branch pacing arm developed pacing‑induced cardiomyopathy, whereas 11.7% of the right ventricular pacing group did. Heart failure hospitalization rates were reported as 1.5% for left bundle branch pacing versus 2.9% for right ventricular pacing.
The report noted differences in clinically important device-related outcomes. The absence of reported pacing‑induced cardiomyopathy in the left bundle branch pacing arm contrasts with the measurable incidence in the right ventricular group. Investigators tracked other safety events and pacemaker data, but the news release did not itemize all procedure‑related complications or specific device‑related adverse events. The source did not report procedural success rates, lead revision rates, or differences in implantation time between the two pacing approaches. These procedure-level details were not provided in the news summary.
An independent data monitoring committee reviewed a planned interim analysis after a median follow‑up of approximately three years. The committee found the primary outcome difference met the trial’s pre‑established threshold for superiority and recommended stopping enrollment early. The steering committee concurred and ended the trial before completing the planned five‑year follow‑up for the full cohort.
All major events had been reviewed and confirmed by an independent, blinded adjudication committee. The trial team reported that the manuscript was published concurrently in a peer‑reviewed journal, and the results were presented as a late‑breaking abstract at the American Heart Association Scientific Sessions 2026.
The investigators listed several explicit limitations. Early termination of the trial can exaggerate apparent benefit and reduces the precision of effect estimates; the source cautioned this could influence interpretation. Most participants had normal baseline left ventricular function, so applicability to patients with pre‑existing reduced ejection fraction remains uncertain. All left bundle branch pacing procedures used a single lead type; the report did not establish whether results generalize to other leads or implantation tools. The news release did not report granular procedural metrics or long‑term device performance beyond the adjudicated clinical events.
The authors recommended targeted follow‑up studies to determine which patients derive the greatest net benefit from physiologic pacing strategies, to compare alternative approaches that engage the heart’s native conduction system, and to evaluate long‑term safety and cost‑effectiveness. Those specific research needs were framed as necessary before guideline updates or widespread changes in standard practice.
The article ends on concrete trial constraints and defined next steps: refining patient selection, comparing different physiologic pacing methods, and collecting longer‑term safety and economic data. These items remain the documented unanswered questions and next research milestones provided in the source.